Introduction
Suppression of apoptosis is a permanent prerequisite for malignancies. Cancer-prone cells must devise antiapoptotic strategies in order to extend their otherwise limited lifespan, bypass apoptotic triggers exerted by activated oncogenes or tumor suppressor genes, proliferate independently from exogenous survival factors, defend themselves against cytotoxic immune cells, and finally, resist chemotherapy and radiation (Thompson, 1995; Hueber and Evan, 1998; Hanahan and Weinberg, 2000) . Accordingly, the activity and regulation of endogenous inhibitors of apoptosis proteins (IAPs) have become a focus of high interest in the past few years (LaCasse et al., 1998; Deveraux and Reed, 1999; Holcik and Korneluk, 2001 ).
Central to initiation and execution of apoptosis is the activation of caspases, a family of cysteine proteases that cleave target proteins at specific aspartate residues (Alnemri et al., 1995; Hengartner, 2000) . The deleterious action of processed terminal execution caspases can be affected by IAPs which implies that IAP-mediated suppression of apoptosis occurs downstream and irrespective of the triggering stimuli (Hengartner, 2000) . The common motif in IAPs is an approximately 70 residues comprising motif, termed the baculovirus IAP repeat (BIR), since this evolutionary conserved protein domain was first identified in the genomes of baculoviruses (Crook et al., 1994) . The BIR motif is present in the various mammalian IAPs in one to three copies. A second motif located near the carboxy-termini of some IAPs, termed the RING domain, appears involved in protein-protein interaction, but was found dispensable under certain circumstances. Human IAP family members, such as c-IAP-1, c-IAP-2 and XIAP, made devoid of their RING domains, retained their apoptosis-suppressive function, indicating that the BIR domains are essential for the apoptosis-suppressive activities of IAPs Roy et al., 1997; Takahashi et al., 1998) . The common function of IAPs is to bind to activated execution caspase-3 and -7 (Roy et al., 1997; Tamm et al., 1998; Shin et al., 2001) .
Among the steadily increasing number of IAPs, survivin has attracted special attention through its involvement in human cancer. Survivin-mRNA is highly expressed in embryonic tissue, specially in liver and kidney, but not detectable in adult differentiated tissue (Ambrosini et al., 1997) . However, survivin is present in most transformed cell lines and malignancies tested to date (Ambrosini et al., 1997; Tamm et al., 1998) . How survivin becomes upregulated in tumorigenic cells is not known. The small 16 kDa protein contains a single BIR domain that is similar to the BIR2 region of XIAP and lacks the RING finger. Survivin appears to inhibit processing of procaspase-3 and -7 and specifically binds both caspases in vitro Deveraux and Reed, 1999; Shin et al., 2001) , although the exact mechanism by which survivin couples in vivo to the caspase cascade has not been completely unravelled. Consistent with the function of an IAP, survivin is a multipotent antiapoptotic protein and rescues from receptor-mediated (FasL) cell death, Bax, caspase-3, -7 and -8 overexpression, growth factor withdrawal, tumour necrosis factor and ultraviolet light Shin et al., 2001; Hoffman et al., 2002) . Moreover, expression of survivin in cancer cells is usually associated with resistance of tumour cells towards a broad spectrum of chemotherapeutic drugs such as Taxol, cisplatin, staurosporine and etoposide (Ambrosini et al., 1997; Tamm et al., 1998; Notarbartolo et al., 2002; Tran et al., 2002) . Thus, poor prognostic clinical outcome may be due, at least in part, to the activity of survivin (Monzo`et al., 1999; Sarela et al., 2000; Wurl et al., 2002) .
A special feature of survivin, that is not shared with other IAPs, is its obvious upregulation in the G2/M phase of the cell cycle, where it was found associated with the mitotic spindle apparatus (Li et al., 1998 Uren et al., 2000; Fortugno et al., 2002) . The contribution of survivin to cell division is evolutionary conserved. In yeast and C. elegans, proper chromosomal separation is strictly dependent on the action of proteins with survivin-like BIR domains (Uren et al., 1999; Fraser et al., 1999) . These proteins in lower organisms, however, lack antiapoptotic activity, indicating that the survival function of the BIR-only containing proteins was superimposed by evolution. In its ancestral role, survivin promotes genetic stability and genome integrity during chromosomal segregation and cytokinesis. More particularly, deletion of the murine survivin gene caused early aberrant development with gross cellular degeneration and irregular cell morphology leading to embryonic death around day 5 post coitum (Uren et al., 2000) . Survivin-deficient embryonic cells had variable nuclear size, irregular nuclear morphology and multinucleation because of the underlying defect in mitotic spindle organization. Notwithstanding its important role for chromosomal separation and cytokinesis, survivin is usually not detectable in normal adult tissue.
The fact that survivin is re-expressed in a variety of human malignancies suggested a close connection to some transformation properties. Alternatively, certain frequently activated oncogenes or mutated tumour suppressor genes could contribute to survivin re-expression in tumorigenic cells. Here we describe for the first time that the expression of survivin is controlled by oncogenic c-H-ras and that upregulation of survivin depends on functional Ras/PI3-K-and Ras/Raf/MEK/ MAPK-signalling pathways.
Results

Survivin is elevated in c-H-ras expressing cell lines
We analysed the expression of survivin and some cell cycle-relevant genes in a series of rat cell lines immortalized by several oncogenes or transformed by cooperating c-H-ras ( Figure 1a) . The 'R' in the clone's name indicates the additional expression of the c-H-Ras oncoprotein, endowing cells with transformation properties. Two cell lines expressed a human c-myc oncogene (M-19 and MR-2), two expressed a mutated murine p53 val135 (p53-11 and p53R-3) and two others had been immortalized by Human Papilloma Virus Type 11 DNA (HPV11; H11-14 and H11R-8). A rare c-H-ras-only transformed cell line (R-1) was also included in the analysis, and normal, nontransfected rat embryo cells (RECs) served as control. Expression of transgenes was verified by Northern-and Western blot analysis (Cerni et al., 1990 (Cerni et al., , 1995 (Cerni et al., , 2002 ; and data not shown).
Survivin was found elevated in the transformed rat cell lines, while its expression was lower or absent in the nontransformed counterparts ( Figure 1a , first and fifth row). Thus, increased survivin expression appeared to correlate with cellular transformation or presence of cooperating c-H-ras rather than on special immortalizing viral or cellular oncogenes. An exception was mutated p53, which increased survivin levels already without additional presence of c-H-Ras. This might be because of a wild-type p53-responsive element in the survivin promoter, which confers inhibition of survivin transcription (Mirza et al., 2002) . The specificity of the survivin signal was confirmed by comparing survivin levels of secondary REC, which had detectable endogenous survivin levels because of their embryonic origin, and the same cell population, transiently transfected with a human survivin-antisense construct. The antisurvivin construct led to a pronounced reduction of REC's survivin level ( Figure 1a , fifth row; compare lanes 10 and 11). To further substantiate the transformed phenotype of the cell lines, some cell cycle-relevant proteins were visualized by appropriate antibodies. With the exception of p53R-3 cells, expression of c-H-Ras was accompanied by downregulation of the cyclin/cyclin-dependent kinase (CDK) inhibitor, p27 KIP1 , and upregulation of p21 WAF1 ( Figure 1a , second and third row). It is well established that p21 WAF1 is involved in the assembly of active cyclin/CDK complexes (LaBaer et al., 1997) and inducible by oncogenic Ras (Robles et al., 1998; Pruitt and Der, 2001) . Reciprocal expression of both cyclin/CDK-complexes modulators was observed in several transformed human and rodent cell lines (Sherr and Roberts, 1999; Pruitt et al., 2000; Pruitt and Der, 2001) .
In order to substantiate the nontransformed nature of the immortalized cell lines by a molecularbiological marker, expression of tropomyosin isoforms was determined. Tropomyosin levels were found low or almost undetectable in transformed cells and, conversely, high in morphologically nontransformed cells (Figure 1a , fourth row) which is in accordance with other reports (Shield et al., 2002, and references therein) . To follow the increase of survivin during cellular transformation, we transfected REC with p53 val135 and c-H-ras and cultivated the cells for at least seven passages as mass cultures (MCs) without selection (Figure 1b) . In nontransfected REC, survivin decreased by the time.
In contrast, in the oncogene-transfected cultures the level of survivin increased dramatically at transfer 5, when transformed cells had overgrown the residual nontransformed REC.
The effect of c-H-Ras was also studied in a human cell system. The nontransformed human keratinocyte cell line, HaCat, was transfected with a c-H-ras plasmid and HPV16 or HPV11 DNA, respectively. Nontransfected HaCat cells had low, but detectable amounts of survivin protein ( Figure 1c, lane 1) . In all three clonal pools (each comprising approximately 200 neoresistant clones), expression of c-H-Ras was accompanied by a significant increase of survivin protein ( Figure 1c, lanes 2-4) , irrespective of the additional transfection of viral oncogenes. We concluded that in mammalian cells, increased survivin levels are a consequence of certain c-H-Ras activities.
Survivin is promptly upregulated by oncogenic c-H-Ras
To distinguish between upregulation of survivin by c-Hras and cellular transformation per se, we took advantage of a ras-construct carrying a MMTV promoter which is inducible by dexamethasone (Dex). The MMTV-rasA-plasmid was transfected together with a hygromycin-resistance gene into the embryonic rat cell line 423. This nontransformed parental cell line has a fibroblastic, flat morphology and is normal with regard to density-dependent growth inhibition, and inability to grow in semisolid substrates (Fuhrmann et al., 2001 ; and data not shown). An additional advantage of 423 cells is their strict requirement for high serum concentration. Among a series of hygromycin-resistant, Dex-induced c-H-Ras(DiR)-transformed colonies, one clone, 423DiR-1, was chosen at random for further characterization.
When in nontransformed 423DiR-1-cells, transcription of c-H-ras transgene was turned on by addition of Dex to the medium, c-H-Ras protein became readily detectable after 6 h and reached a maximum within the next 6 h which remained constant thereafter ( Figure 2a , left panel). Conversely, upon withdrawal of Dex from the culture medium Ras protein successively decreased from the second hour onwards and was undetectable /c-H-ras-transfected REC (p53R MC), respectively. Cell lysates were prepared on day 3 (passage 1), 9 (passage 3), 16 (passage 5), 23 (passage 7) and 30 (passage 9) after transfection. A quantity of 20 mg of protein lysates was subjected to Western blot analysis with antibodies against Ras, survivin, tropomyosin and actin as loading control. (c) Expression of survivin in c-H-ras-transfected human HaCat cells. HaCat cells were transfected with CMV-c-H-ras and a neo-resistant gene without (HaCat-R-pool) or with HPV16 (HaCat-H16R-pool) or HPV11 DNA (HaCat-H11R-pool), respectively. Approximately 200 G418-resistant colonies of each experimental group were pooled and cell lysates subjected to Western blot analysis, using an antibody against human survivin, as described above after 36 h (Figure 2a , right panel). Since the amounts of endogenous Ras proteins were below detection limit, the half-lifetime of oncogenic c-H-Ras was calculated from densitometric evaluation of the Western blot (data not shown) and was found to be approximately 8 h, which is shorter than that calculated for other Ras-transformed cell lines (Jaggi et al., 1986) .
Expression of survivin followed closely that of the oncoprotein, with a 2 h delay ( Figure 2a ). Upon induction of c-H-Ras, survivin increased from the eighth hour onward and reached a maximum at 36 h. Conversely, 2 h after withdrawal of Dex from the transformed 423DiR-1-cells, survivin decreased. The reduction of survivin level lagged behind that of c-H-ras. An almost identical c-H-Ras-mediated up-and downregulation was found for cyclin D1 (Figure 2a , fifth row) which is in agreement with recent reports on the induction of cyclin D1 by the Ras oncoprotein (Robles and Conti, 1995; Robles et al., 1998) . The transformation-associated inverse correlation between p27 KIP1 and tropomyosin species lagged considerably behind c-HRas-mediated regulation of survivin and cyclin D1, respectively (Figure 2a, third and fourth row), suggesting that the former two genes are more distant targets of c-H-Ras activity.
At variance with the prompt up-and downregulation of c-H-Ras and survivin expression, morphological alterations were evident only after approximately 36 h after addition or omission of Dex (data now shown). Obviously, a complex and time-consuming interplay of intracellular signalling cascades is required for morphological changes.
In Figure 2b , we demonstrate that neither Dex nor its solvent ethanol had an effect on survivin level in the parental cell line 423.
We then generated from genomic DNA a part of the human survivin promoter, comprising 577 base pairs adjacent to the start codon, and fused it to a luciferasegene. This construct, together with increasing amounts of c-H-ras-DNA, was transiently transfected into the nontransformed rat cell line, FR3T3. Figure 2c shows the c-H-ras dose-dependent increase of the survivin Figure 2 (a) Induction of survivin by overexpression of c-H-ras transgene. Nontransformed 423DiR-cells, expressing a dexamethasone-inducible c-H-ras (DiR) oncogene, were cultivated in drug-less medium for at least 7 days before dexamethasone (Dex; 1 mm) was added to the cultures (left panel). Transformed 423-cells were cultured in the presence of Dex for at least 7 days before Dex was removed from growing cultures (right panel). Cell lysates were prepared at the indicated time points, and 20 mg of total lysates was subjected to immunoblotting with antibodies against Ras, survivin, tropomyosin, the cyclin/CDK-inhibitor p27 KIP1 , cyclin D1 and actin as loading control, respectively. (b) Expression of survivin in parental 423-cells. 423-cells were treated with dexamethasone (Dex; 1 mm) or the solvent ethanol for 48 h, respectively. A quantity of 20 mg of total lysates was subjected to Western blot analysis with antibodies against survivin and actin as loading control. (c) Induction of human survivin promoter activity upon coexpression of c-Hras. The nontransformed rat cell line FR3T3 was transiently transfected with pGL-hum survivin promoter 577-luc and with increasing amounts of c-H-ras-expressing plasmid pEJ6.6. The amount of the reporter plasmid was 1 mg/well. The concentration range of pEJ6.6 was from 0.01 ng/well to 1 mg/well and pUC19 was added to give a constant DNA amount of 2 mg/well. At 2 days after transfection, cells were harvested and luciferase activity was measured in a Luminoskan RS (Labsystems) and protein concentration was used for normalization. Cells cotransfected with 0.01 ng pEJ6.6 were used as baseline. The amount of pEJ6.6 plasmid is shown on a logarithmic X-axis promoter activity, with a maximal induction of 200% between 50 and 100 ng c-H-ras-DNA. The decline in survivin promoter activity at higher c-H-Ras levels presumably reflects the squelching phenomenon, often observed when supraphysiological amounts of multifunctional proteins are used (Natesan et al., 1997).
c-H-Ras-induced survivin expression is independent of cell cycle progression
Recently, it was reported that survivin is upregulated in the G2/M phase of the cell cycle (Li et al., 1998 Kobayashi et al., 1999; Uren et al., 2000; Fortugno et al., 2002) . Therefore, we wondered whether the increase of survivin levels was an effect of c-H-Ras-mediated cell cycle alteration. More specifically, a Ras-mediated increase of the G2/M fraction of cells could bias survivin upregulation.
Cell cycle distribution profiles were performed of nontransformed 423DiR-1-cells at 2-4-h intervals after addition of Dex to the medium. As shown in Figure 3 , upon induction of c-H-ras, the fraction of S phase cells increased rapidly from 25% to approximately 40% within 8 h at the expenses of cells in G1 (Figure 3a ) and remained at a similar rate thereafter (Figure 3b , right panel). In contrast, the fraction of cells in G2/M remained constant at approximately 12% during the entire observation period (Figure 3a and b, right panel). The early increase in S phase cells, already observable 2 h after c-H-ras induction, was a transient effect of the Dex-solvent, ethanol, as revealed by cell cycle kinetics of parental 423-cells and normal REC, respectively, treated with Dex and/or ethanol (data not shown).
We arrested growing nontransformed and transformed 423DiR-cells either in G1 by mimosine, in G1/ early S phase by thymidine or in G2/M by nocodazole, and compared the survivin levels in the different cell cycle phases (Figure 3c ). For comparison, HeLa cells were concomitantly treated and analysed. The efficiency of cell cycle arrest was confirmed by FACS analysis (data not shown). Interestingly, in transformed 423DiR-cells, survivin levels remained constant at all cell cycle phases ( Figure 3c , lanes 6-8), whereas nontransformed 423DiR-cells had elevated survivin levels only in G2/M. The reason for the more pronounced survivin expression in both untreated transformed cell lines might be explained by the sensitivity of the cells towards cell cycle arrest.
In order to investigate whether alteration of survivin degradation (mediated for instance by c-H-Ras) is of importance, we treated nontransformed 423DiR-1 cells with the proteasome inhibitor MG-132. If degradation played a major role in the regulation of survivin levels, an increase should become quickly evident. This, however, was not the case. As shown in Figure 3d , the survivin levels remained constant, whereas proteasomedegradable mdm2 accumulated as expected (Figure 3d ; second row) (Chang et al., 1998) . Therefore, it appeared unlikely that the prompt induction of survivin upon c-H-ras activation (Figure 2a ) was because of altered degradation processes.
c-H-Ras-induced survivin expression is independent of cellular proliferation
Since transformed cells have higher proliferation rates than nontransformed, the question arose whether survivin might rather be associated with proliferation than c-H-Ras expression. Two approaches were performed. In a first setting, the growth of transformed 423DiR-1 cells was compromised by both, serum reduction or shift of the cultures to 321C. Both conditions reduced within 48 h the fraction of S phase cells from 35% to approximately 20-25%, as determined by FACS analysis (data not shown). Despite growth reduction, the level of survivin remained elevated (Figure 3e) . In a second approach, we took advantage of the fact that nontransformed 423DiR-1 cells express survivin physiologically only in G2/M, but not in G1 (Figure 3c ). When in these G1-arrested cells c-H-Ras was induced, survivin became promptly upregulated ( Figure 3f ). This strongly supports our notion that survivin is controlled by the c-H-Ras oncoprotein and not by cellular proliferation.
Survivin expression is controlled by the PI3-K and MEK1 pathways
In order to identify intracellular Ras-pathways involved in the upregulation of survivin, we generated a series of stably transformed c-H-ras expressing 423 subclones (423R-cell lines) which differed among each other with regard to expression levels of the transgene (Figure 4a ) and cellular morphology (Figure 4b and c; and data not shown). Two of them, 423R-2 and 423R-4, were chosen on the basis of different c-H-Ras levels and distinct transformed morphology, with 423R-4 cells being extreme in both criteria.
When the PI3-K inhibitors, LY294002 and Wortmannin, were added, a concentration-dependent decrease of survivin was observed in both the cell lines after 24 h (Figure 4d ). LY294002 appeared in several independent experiments more potent than Wortmannin which is probably because of different stabilities of the drugs in culture medium (Kimura et al., 1994) . Similar to the PI3-K-inhibitors, albeit less effectively, the MEK1 inhibitor U0126 also reduced the level of survivin in 423R-2 and -4 cells by approximately 40 and 60%, respectively (Figure 4d, lanes 4 and 10) . Since the results suggested that survivin expression might be controlled by both pathways, we treated 423R-2 and -4 cells with combinations of each PI3-K-inhibitor and U0126. Indeed, when LY294002 and U0126 were applied simultaneously, expression of survivin was abolished in 423R-2 cells and dramatically reduced in 423R-4 cells (Figure 5a, lanes 4 and 12) . A significant decrease of survivin levels was also observed in both cell lines treated with Wortmannin and U0126 (Figure 5a , lanes 7 and 15). Survivin expression was affected more severely in treated 423R-2 cells than in 423R-4 cells. A reasonable explanation might be the overabundance of c-HRas protein in 423R-4 cells which prevented complete inhibition of phosphorylated Erk2 by U0126 (Figure 5a , second row, lanes 12 and 15). Nevertheless, even under these rather extreme circumstances, survivin was dramatically reduced when both Ras-pathways were reasonably inhibited. The traces of phosphorylated Erk2 in 423R-4 cells obviously sufficed for normal cyclin D1 expression (Figure 5a , fourth row, compare Growing, nontransformed 423DiR-1-cells were treated with the proteasome-inhibitor MG-132 (10 nm). Cell lysates were prepared at the indicated time points, and 20 mg of protein lysates was subjected to Western blot analysis with antibodies against survivin, mdm2 and actin as loading control. (e) Survivin expression remains high in transformed 423DiR-1-cells at growth-limiting conditions. Transformed 423DiR-1-cells were cultured at normal (371C; 10% FCS) or growth-limiting conditions (321C and 10% FCS, or 371C and 0.1% FCS, respectively). A quantity of 20 mg of total lysates was subjected to Western blot analysis with antibodies against survivin and actin as loading control. (f) c-H-Ras-mediated survivin expression occurs independently from cellular proliferation. Nontransformed 423DiR-1-cells were arrested in G1 with mimosine for 24 h. For the last 8 h, cells were treated with dexamethasone (Dex; 1 mm) or ethanol, respectively. A quantity of 20 mg of cell lysates was subjected to Western blot analysis with antibodies against Ras, survivin, and actin as loading control lanes 12 and 15), but not for survivin expression, indicating that both genes are regulated independently from each other. Although U0124 is the supposed inactive control compound to U0126, it affected in three independent experiments the survivin expression in 423R-2 (but not 423R-4) cells. The reason is unclear.
To demonstrate the effect of LY294002 and/or U0126 on the survivin-promoter activity, MR-2 cells (shown in Figure 1a , lane 8) were transiently transfected with the survivin-promoter construct and treated with the inhibitors for 2, 4 and 6 h. Combined treatment induced a 70% reduction of the promoter activity within 6 h (Figure 5b ).
c-H-Ras-induced survivin localizes to the mitotic apparatus
We determined the localization of c-H-Ras-inducedand basal level-survivin to the mitotic apparatus by immunofluorescence microscopy with the survivin antibody 8E2 (Li et al., 1998) . Figure 6a -c shows survivinstaining patterns in transformed 423DiR-1 cells at three different stages of mitosis. The staining was specific for the survivin antibody, since omission of the first antibody did not resolve any cellular structures (data not shown). Although the cells had not been pretreated with Taxol in order to stabilize microtubuli, there was a clear staining of the spindle apparatus at aequatorial metaphases and anaphase, similar to what has been described for Taxol-pretreated HeLa cells (Li et al., 1998) . In contrast to the unequivocal localization of survivin with mitotic spindles of transformed cells, the metaphase staining pattern in the nontransformed counterparts was cytosolic, with no discernible association with special spindle structures (Figure 6d-f) . Only very rarely, mitotic spindles stained positive for survivin in these cultures which is in agreement with the modest survivin expression induced in G2/M (Figure 3c, lane 2) . Similar to the c-H-Ras-negative 423DiR-cells were metaphases of transformed 423DiR-cells treated with either LY29004 and/or U0126 (Figure 6g-i; and data not shown). This implies that modifications by both 1 and 7) or treated cultures (lanes 2-6 and lanes 8-12, respectively) were prepared for immunoblotting using an antibody against survivin. Actin was used as loading control. During drug exposure, serum was reduced to 0.1% Ras-pathways are required for survivin localization to spindle structures. What was common in all cell preparations, irrespective of Ras-expression or chemical treatment, was survivin staining of midbodies in late telophase.
Inhibition of c-H-Ras-induced survivin is associated with apoptosis
We determined the number of intact nuclei in 423R-2 and -4 cells, in which PI3-K and/or MEK1 have been Figure 5 Downregulation of survivin by simultaneous inhibition of PI3-K and MEK1. 423R-2 and -4 cells were cultivated in medium with 10% FCS and selection drugs. Serum concentration was reduced to 0.1% from growing cultures and the PI3-K-inhibitors, LY294002 (20 mm) or Wortmannin (100 nm) and the MEK1-inhibitor, U0126 (10 mm), were added in various combinations for 24 h. Cell lysates from untreated cultures, that is, 10% FCS (lanes 1 and 9), cells cultivated in 0.1% FCS (lanes 2 and 10) or drug-treated cultures (lanes 3-8 and 11-16, respectively) were prepared for immunoblotting using antibodies against survivin, phosphorylated or total Erk1/2, and cyclin D1. Actin served as loading control. (b) Downregulation of human survivin promoter upon inhibition of PI3-K and MEK1. Transformed MR-2 cells were transiently transfected with pGL-hum survivin promoter 577-luc in 24-well-plates. At 2 days after transfection cells were treated for 2 (dark gray bars), 4 (light gray bars) and 6 (white bars) h with U0126 (10 mm), LY294002 (20 mm) or U0126 plus LY, respectively. DMSO-treated controls (black bars) were set as 100% and inhibitor-treated lysates are shown with7s.e.m. Data from three independent experiments are presented inhibited for 24 h (Figure 7a ). Whereas serum withdrawal alone slowed down the proliferation rate of both transformed cell lines without any indication of apoptosis, drug-mediated suppression of survivin was accompanied by the appearance of fragmented nuclei and a loss of viable attached cells. In 423R-2 cells, addition of LY294002 decreased the survivin level by approximately 40% (Figure 5a , lane 3) and caused a 35% cell reduction within 24 h (Figure 7a ). When survivin expression was completely abolished by the additional inhibition of the MEK1-signalling pathway (Figure 5a , lane 4), cell death was dramatically enhanced (Figure 7a ). At this condition, almost 90% of the initial cell number was lost by cell death, and among the remaining cells a considerable fraction of 45% revealed fragmented nuclei (data not shown). Similarly, in 423R-4 cultures treated with LY294002 plus U0126, the number of attached cells was reduced to less than 40% (Figure 7b) , with an apoptosis rate of 17% (data not shown). The proapoptotic effect of drug-inhibited MEK1 was specific since combining LY294002 with the inactive compound U0124 was significantly less harmful to both the cell lines. When LY294002 was replaced by Wortmannin, apoptotic nuclei and a reduction of viable cells were present in both the cell lines, albeit at a less extent than with LY294002 (data not shown).
The same experimental setting was applied to RECs, parental 423 cells and nontransformed and transformed 423DiR-cells. Figure 7c shows the different sensitivities of these four cell populations towards a 24-h serum reduction. While proliferation of RECs was only reduced (compared to 10% FCS cultures), substantial cell loss occurred in parental 423 cells (Fuhrmann et al., 2001) and nontransformed 423DiR-cells. In contrast, transformed 423DiR cultures showed no signs of apoptosis and proliferated faster than RECs. However, inhibition of PI3-K and/or MEK1 at limited serum concentration induced massive apoptosis in transformed 423DiR-cells, while the nontransformed counterpart remained almost unaffected by the same treatment (Figure 7d ). The increased proliferation of REC in the presence of LY294002 was a surprise and warrants further investigations.
Reduction of survivin level inhibits c-myc/c-H-rasmediated focus formation
The efficient transformation of rodent cells by cooperating oncogenes such as c-myc and c-H-ras is well established, although the exact mechanism underlying this synergism has not been fully elucidated. Therefore, we investigated the contribution of endogenous survivin to c-myc/c-H-ras-mediated focus formation of primary REC. Indeed, cotransfection of a survivin-antisense construct, whose effect on survivin levels was shown in Figure 1a , lane 11, reduced the number of dense foci by approximately 50% (Table 1) . Similarly, a decrease of G418-resistant colonies in c-myc/c-H-ras/ Figure 6 Localization of survivin in untreated or LY/U0126-treated transformed and nontransformed 423DiR-1-cells. Transformed (a-c) and nontransformed (d-f) 423DiR-1-cells were plated on coverslips and cultured in DMEM with 10% FCS, with or without Dex. LY294002 (20 mm) and U0126 (10 mm) were added for 6 h to transformed 423DiR-1 cells (g-i). Growing cells were prepared for immunofluorescence using an antibody against survivin (8E2) and Cy3-labelled secondary antibody (middle row). DAPI was used for counter-staining (left row). Different stages of mitosis are indicated. M: metaphase, A: anaphase, T: late telophase, MB: midbody survivin-antisense-transfected cultures was observed that was because of the reduced number of outgrowing transformed clones (Table 1 ). This suggests that one of the activities, by which activated c-H-Ras contributes to cellular transformation -at least in certain oncogene cooperations-might be based on upregulation of antiapoptotic survivin.
Discussion
Survivin, an inhibitor of apoptosis, is frequently overexpressed in malignant cells and we reasoned that c-HRas oncoprotein might be an upstream regulator of survivin. Expression of a dexamethasone-inducible c-Hras construct, transfected into an apoptosis-sensitive rat cell line, allowed to follow cell cycle regulation, cellular localization and antiapoptotic function of c-H-Rasinduced survivin. Steady increase of survivin protein was observed 2 h after c-H-Ras expression, the minimal time needed for transcription and translation processes. As relevant Ras-pathways for survivin upregulation and activity, the Ras/PI3-K and Ras/Raf/MEK/MAPK were identified. Chemical inhibition of both signalling cascades abolished survivin expression and was associated with massive apoptosis. Moreover, the synergistic action of c-myc-with c-H-ras-oncogene in cellular transformation was severely compromised by a survivin-antisense construct. To our knowledge, this is the first report on the regulation of endogenous, antiapoptotic survivin by oncogenic c-H-Ras.
Four aspects of Ras-induced survivin appear of special interest: (i) antiapoptotic pathways, (ii) contribution (i) Oncogenic Ras plays a key role not only in the genesis, but also in the maintenance of malignancies. Progression of malignant melanomas in INK4a null mice, induced by a tetracycline-inducible H-ras oncogene, was strictly dependent on the presence of Ras, since withdrawal of tetracycline in this in vivo tumour model led to increased apoptosis rates and rapid regression of tumours (Chin et al., 1999) . This indicated that some Ras activities were permanently required for tumour cells survival.
An hourglass enzyme for survival is PI3-K (for review see Cantley, 2002; Vivanco and Sawyers, 2002) . A plethora of distinct signals can converge on PI3-K, such as phosphotyrosine residues of growth factors or adaptors, non-nuclear oestrogen, integrin-dependent cell adhesion and G-protein-coupled receptors (Simoncini et al., 2000; Cantley, 2002; Tran et al., 2002) . Importantly, physical interaction of PI3-K with Ras proteins leads to activation of this key kinase (Rodriguez-Viciana et al., 1994 . While upstream activation of PI3-K is well understood, elucidation of downstream events is scarce because of the limited availability of suitable apoptosis-prone cell systems. However, in a few recent reports, survivin was identified as downstream target of activated PI3-K. Human coronary endothelial cells resisted hypoxic conditions via PI3-K/NF-kB/survivin pathway (Zhu et al., 2001 ). In addition, VEGF protected endothelial cells from chemotherapeutic damage in a PI3-K/Akt/survivindependent manner (Tran et al., 2002) . Our serumsensitive 423 cell line and its derivatives represent another suitable cell model, by which we show here that the PI3-K/survivin-pathway contributes to the survival of cells at risk.
For several cell types, activation of the Raf/MEK/ MAPK pathway is needed to counteract apoptotic triggers (Holmstrom et al., 1998; Le Gall et al., 2000; Peyssonnaux and Eyche`ne, 2001 ). Similar to the spectrum of upstream activators of PI3-K, a variety of exogenous and endogenous mitotic signals stimulate MAPKs (Volmat and Pouyssegur, 2001; Peyssonnaux and Eyche`ne, 2001 ) and only recently detailed insights into MAPK-mediated modifications of downstream targets have emerged. As example, Erk-mediated phosphorylation of the ubiquitous transcription factor Sp1 on threonine 453 and 739 is required for its enhanced binding to DNA and hence function (Merchant et al., 1999; Milanini-Mongiat et al., 2002) . Our data suggest that survivin might be another downstream target of MAPK and elucidation of how Erk contributes to survivin activity is a challenging future task. However, efficient upregulation and function of endogenous survivin as antiapoptotic protein in our 423-derived cell lines demand for stimulated PI3-K plus MEK1, both provided congenially by mutated Ras oncoproteins.
(ii) It is an attractive hypothesis that efficient cooperation of oncogenes is based on mutual neutralization of triggered apoptotic pathways (Hueber and Evan, 1998) . In some cell types, such as primary REC (our unpublished observation) or Rat-1 cells (Kauffmann-Zeh et al., 1997), high levels of oncogenic Myc are only tolerated by concomitant expression of activated ras oncogenes (Kauffmann-Zeh et al., 1997; Fuhrmann et al., 1999) . Our data suggest that increased levels and presumed modifications of survivin appear to be required when normal REC are subjected to oncogenemediated transformation. This is deduced from the finding that reduction of endogenous survivin levels in REC by means of a survivin-antisense construct profoundly affected the outgrowth of c-myc/c-H-rasinduced dense foci and transformed clones, respectively. Since the oncogene-transfected REC cultures were replated at a defined cell number, immediate effects of the survivin-antisense construct on cellular viability did not bias the results. Thus, the proven cooperation of cmyc with c-H-ras in primary REC (Land et al., 1983; Cerni et al., 1995 Cerni et al., , 2002 Simonitsch et al., 2001) was hampered by reduced amounts of endogenous survivin. We are currently investigating whether survivin is also important for other oncogene cooperation models.
(iii) There has been some discussion concerning the localization of survivin during mitosis. Li et al. (1998) found survivin attached to microtubules in Table 1 RECs were transfected with the indicated genes together with a neo-resistance gene and replated in five to seven dishes at 3 Â 10 5 per 60 mm culture dish. For focus formation, serum was reduced to 5% after 2 days. For G418-resistant colonies, selection drug (200 mg/ml) was added 2 days after transfection. Dishes with dense foci were stained with Giemsa between day 8 and 11. Dishes with G418-resistant colonies were stained with Giemsa after 11-17 days. Colony morphology was determined by microscopic inspection. tr.phenotype: transformed phenotype (i.e. multilayered colonies with criss-cross growth pattern) Taxol-treated HeLa cells. At variance, Uren et al. (2000) found survivin colocalized with the constitutively expressed centromere-associated protein, CENP-B, during all stages of mitosis. By means of survivin-antibodies recognizing distinct epitopes, two survivin pools were identified, one nuclear and one cytosolic (Fortugno et al., 2002) . We found survivin-staining of mitotic spindle structures in untreated Ras-transformed cells, whereas short-term treatment with LY294002 plus U0126 (in medium with 10% FCS) resulted in cytosolic, diffuse localization of survivin (Figure 6g-i) , similar to the survivin staining pattern of nontransformed metaphase cells (Figure 6d-f) . Even a 2-h treatment of transformed 423DiR-1 cells with LY294002 and/or U0126 markedly diminished the localization of survivin to the mitotic spindle apparatus (data not shown). This suggests that, apart from direct or indirect transcriptional activation of survivin by c-H-Ras, other Ras-mediated effects on downstream targets are required to render survivin functional in its ancient role as protector of genome integrity (Li et al., 1998; Fraser et al., 1999; Uren et al., 1999 Uren et al., , 2000 . In this context, it appears interesting that the Raf/MEK/MAPK pathway is necessary also for the G2/M progression, where 40% of MAPKs was found associated with microtubuli (Hayne et al., 2000) . Our finding that survivin staining pattern (and presumably its function too) at mitosis is influenced by the presence of a multifunctional oncoprotein might be a reasonable explanation for our early, at that time puzzling data on karyotype stability of oncogeneimmortalized and -transformed rat cell lines (Cerni et al., 1986) . Whereas immortalizing oncogenes such as c-myc, mutated p53 or HPV16 gave rise to heteroploid karyotypes, transforming oncogenes like c-H-ras or Polyoma middle T preserved the diploid karyotype of transfected REC even in the presence of immortalizing oncogenes.
(iv) Activating mutations in ras oncogenes have been detected in a wide variety of human malignancies. The overall incidence is about 30%, with the highest incidence of 95% in pancreatic carcinomas (Boss, 1988; Adjei, 2001) . It is intriguing that malignancies with obligatory or frequent ras-gene mutations such as colon-and pancreatic carcinoma and melanoma produce high amounts of survivin . Increased expression of survivin mRNA and protein correlates with both, resistance towards treatment modalities and an unfavourable prognosis (Monzoè t al., 1999; Sarela et al., 2000) . Our data show that c-H-Ras-induced survivin is independent of both, cell cycle progression and cellular proliferation which might well correspond to the abundance of survivin-positive human tumour cells in histologic samples, irrespective of the mitotic index of the tumours (Grossman et al., 1999) . It is obvious that constant expression of functional survivin throughout the cell cycle is advantageous for transformed cells. A recent study on the activation of a survivin promoter-luciferase construct transfected into human cancer cells showed that (unidentified) cancer cell genes act positively on the survivin promoter (Bao et al., 2002) . We suggest that mutated ras genes might represent one class of these survivin-activating genes.
Materials and methods
Cell culture and transfection
The human HaCat cell line (kindly provided by N Fusenig, DKFZ, Germany) was cultivated in DMEM and 10% FCS, supplemented with penicillin/streptomycin (P/S) at 7.5% CO 2 . Cells were transfected with Human Papilloma Virus Type 16 (HPV16) and Type 11 (HPV11) DNA, respectively, and/or a CMV-c-H-ras construct, together with a neoresistance gene. DNA (20 mg) was added to cultures (in 10 mm dishes) by the calcium-phosphate-precipitation method. Geneticin (G418; Life Technologies) was added 2 days later at a concentration of 800 mg/ml. After the selection period, approximately 200 neo-resistant clones of each group were pooled. HeLa cells were cultivated in RPMI, P/S and 10% FCS at 5% CO 2 .
Transformed and nontransformed rat cell lines were generated by transfecting various oncogenes together with a neo-resistance gene into primary RECs. Individual clones were isolated and established into cell lines as described (Cerni et al., 1990 (Cerni et al., , 1995 Simonitsch et al., 2001) . Cells were cultured in DMEM, P/S and 10% FCS, in presence of G418 (200 mg/ml). The cell lines, subjected to survivin analysis, were chosen at random from a large collection of established cell clones piled up in the last years, which had been generated as neo-resistant clonal isolates from different preparations of primary REC (Cerni et al., 1990 (Cerni et al., , 1995 (Cerni et al., , 2002 . All cell lines were used at low passage numbers, that is, between transfer 8 and 20 after clonal isolation.
The nontransformed, G418-resistant embryonic rat cell line, 423, which was initially immortalized by Human Papilloma Virus type 11 DNA, was supertransfected with either the plasmid pEJ6.6, encoding a constitutively activated c-H-ras oncogene or the MMTV-rasA construct, expressing a Dexinducible oncogenic version of the c-H-ras gene (DiR) (Jaggi et al., 1986) together with a hygromycin-resistance gene. In the MMTV-rasA plasmid, the oncogenic version of c-H-ras is induced upon addition of Dex (1 mm) to the culture medium. The MMTV-LTR contains a sequence element located between nucleotide position À59 and À202 which confers glucocorticoid hormone inducibility (Jaggi et al., 1986) . Transfected 423-cells were replated 20 h later and hygromycin (50 mg/ml) was added after 2 days. The medium with selection drugs was changed twice a week. Cultures transfected with MMTV-rasA were kept in Dex (1 mm) until otherwise stated. Individual transformed colonies were isolated and further propagated under selection condition and designated 423DiR-lines. 423-derived cell lines expressing a constitutively activated c-H-ras oncogene were designated 423R-lines. For transient transfection, plasmidal DNA was removed from the cells after 20 h and the cultures incubated for additional 40 h.
For cell cycle arrest, growing cells were treated for 16-20 h with mimosine (400 mm) to arrest in G1, thymidine (2 mm) to arrest in late G1/early S phase and nocodazole (0.4 mg/ml) to accumulate in G2/M. Primary RECs were prepared from 15.5-gestation-day-old embryos of Fisher rats as described (Cerni et al., 1990 (Cerni et al., , 1995 . At 24 h later, cultures were transfected with 5 mg pSPc-myc DNA, coding for human c-myc, 5 mg pEJ6.6 plasmid and 10 mg survivin-antisense construct or empty pSP-vector. Cells were replated after 20 h at 3 Â 10 5 cells per 60 mm dish and stained with Giemsa after 8-11 days.
Construction of survivin-antisense plasmid The 1.6 kb cDNA of survivin was cut from pT3T7d (IMAGGp998A151965; Resource Center/Primary Database of the Human Genome Project, Berlin) with EcoRI (5 0 ) and HindIII (3 0 ) and cloned into the 5 0 -HindIII-and 3 0 -EcoRI sites of the expression vector pSP (Cerni et al., 1995) .
Protein lysates and immunoblots
Growing cells were harvested by scraping, washed twice in cold PBS and lysed in RIPAII (500 mm NaCl; 50 mm TRIS/HCl pH 7.4; 0.1% SDS; 1% NP-40; 0.5% Na-DOC; 0.05% NaN 3 ) for 30 min on ice. Lysates were sonificated, centrifuged at 12 000 g and the supernatants were used as total cell lysates. Protein concentration was determined by Bradford protein assay (Pierce). A quantity of 20 mg total protein per lane was separated by 12% SDS-PAGE on Mini Protean III (Bio-Rad) and transferred to PVDF membranes (PALL). Membranes were blocked with 5% milk powder in 0.05% Tween-PBS, incubated with the specific antibodies and the secondary antibody diluted in 1% milk powder/Tween-PBS. Detection of the target proteins on the membranes was performed using the West Pico Chemiluminescent Kit (Pierce) on Kodak X-OMAT.
Luciferase reporter assay
A 577-bp (-597 to -21 from ATG position) fragment of the human upstream region of survivin was generated by PCR from genomic DNA of HeLa cells. The positions of the primers according to NCBI gene bank sequence U75285 are 2214 (5 0 -GGCACCCTGTAAAGCTCTCC-3 0 ) and 2790 (5 0 -CAACGGGTCCCGCGATTCAA-3 0 ). The Pfu-generated PCR product was treated with T4 kinase and directly cloned into the SmaI site of pGL3-basic.
Cells (6 Â 10 4 ) were seeded into 24-well plates, transfected by calcium-phosphate-precipitated DNA and harvested 48 h thereafter. U0126 (10 mm) and/or LY294002 (20 mm) were added for the last 2-6 h. Firefly luciferase was detected with the Luciferase Reporter Sytem (Promega) according to the manufacturer's instruction and measured in a Luminoskan RS (Labsystems Oy, Finland).
Antibodies and chemicals
Anti-p21 WAF1 (C-19), anti-p27 KIP1 (F-8), anti-mdm2 (SMP14) and anti-survivin (A-19) were purchased from Santa Cruz, and anti-p21 ras was from DAKO Diagnostics. Anti-cyclin D1 and anti-survivin antibody (8E2) were obtained from NeoMarkers. Anti-human-survivin (Ab 469) was purchased from Abcam Ltd. Antibodies directed against bi-phosphorylated Erk1/2, anti-actin and anti-tropomyosin were purchased from Sigma. Antibody recognizing total Erk1/2 was from Upstate Biotechnology. Secondary anti-mouse, anti-goat and antirabbit-peroxidase conjugated antibodies were obtained from Calbiochem. Cy3-conjugated anti-mouse antibody was from Jackson.
The MEK1-inhibitor U0126 and its inactive derivate U0124 as well as the PI3-K-inhibitors, Wortmannin and LY294002 were purchased from Calbiochem. l-mimosine, thymidine and nocodazole were obtained from Sigma.
FACS analysis
Nontransformed cells of the c-H-ras-inducible 423-subclone, 423DiR-1, were cultured in DMEM with 10% FCS without the hormone and seeded in 60 mm dishes for at least 2 days before FACS analysis. Dex was added and cells were harvested at regular intervals during a 24 h observation period. Cells were fixed overnight in 70% ice-cold ethanol, washed in PBS and resuspended in 1 ml PBS containing 5 mg/ml propidium iodide (Sigma) and 100 mg/ml RNaseA (Sigma). Samples were incubated for 30 min at 371C and placed at 41C before flow cytometry analysis. Samples were analysed in a Becton Dickinson FACSCalibur system using CELLQuest software.
Immunofluorescence
Transformed and nontransformed 423DiR-1-cells were plated on coverslips and cultivated in the appropriate media for at least 48 h before fixation. LY294002 and/or U0126 were added for 6 h before cell preparation. Growing cells were washed twice with PBS, fixed with 2% formaldehyde/PBS for 20 min at room temperature, washed twice with PBS, permeabilized with 0.2% Triton X-100/PBS for 20 min and saturated with 0.2% fish gelatine. Coverslips were incubated with mAb 8E2 to survivin (10 mg/ml), followed by Cy3-labelled second antibody. DAPI (1 mg/ml) in DAKO Fluorescent Mounting Medium was used for counterstaining. Cells were analysed and pictured on a Nikon Microphot-FXA equipped with a Nikon FX-35DX.
Determination of apoptosis
Constitutively transformed 423R-2 and -4 cells, transformed and nontransformed 423DiR-1 cells, the parental cell line 423 and normal REC were cultured in 24-well plates in DMEM with 10% FCS. Prior to addition of PI3-K-and MEK1-inhibitors, serum was reduced to 0.1%. After 24 h, cells were washed twice in PBS, fixed with 3% formaldehyde/PBS for 20 min, carefully rinsed twice with PBS and stained with DAPI (1 mg/ml). Intact and fragmented apoptotic nuclei were counted in a Nikon Elipse TE300 microscope.
